8. Ad hoc statement: Change of strategy necessary
Covid-19: What is the current infectious situation? Like the rest of Europe and the rest of the world, Germany is currently transitioning into the endemic-epidemic phase of the SARS-CoV-2 pandemic. The currently dominant virus variants (Omicron BA4 and BA5) are characterized by a very high level of contagiousness and, at the same time, a very low disease burden. Even among the very elderly residents of nursing homes, who are considered particularly vulnerable, the severity of the disease and the hospitalization rate decreased significantly under the Omicron variant and after the vaccination campaign; mortality compared to 2020 even increased by more than 90%. The currently dominant variants have led to a significant increase in infections among those vaccinated and those who have recovered, with some clinical signs of a flu-like infection, without this being associated with a noticeable overload on the healthcare system and critical infrastructure. The few cases of overload reported were not a result of increased use of intensive care resources, but rather the consequence of isolation measures for staff that were ordered regardless of any symptoms.
Read more
First publication date: 24.06.2022
Downloads
Abstract: 8. Ad-hoc-Stellungnahme: Strategiewechsel notwendig
The 8th ad hoc statement by the theses paper author group deals with the fact that natural infection and vaccination have now led to broad immunity in the population. In the future, identifying those who are actually vulnerable and prioritizing their protection will be essential. As of: September 15, 2022, 6:00 p.m
Abstract: Pandemic management – change in strategy necessary and overdue
The 8th ad hoc statement of the Thesis Paper Authors' Group deals with the fact that in the meantime natural infection and vaccination have led to broad immunity in the population. In the future, identification of the truly vulnerable and prioritization on their protection will be essential. Status: September 15, 2022, 6:00 p.m
Keywords (English)
Covid-19, Epidemiology, Pandemic, prevention, SARS-CoV-2, sociopolitical relevance
Literature
European Center for Disease Prevention and Control. Long-term qualitative scenarios and considerations of their implications for preparedness and response to the COVID-19 pandemic in the EU/EEA. August 2022. ECDC: Stockholm; 2022. https://www.ecdc.europa.eu/en/publications-data/long-term-qualitative-scenarios-and-considerations-their-implications (accessed on September 12, 2022) Stefan Pilz, Verena Theiler-Schwetz, Christian Trummer, Robert Krause, John PA Ioannidis, SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity, Environmental Research, Volume 209, 2022, 112911, ISSN 0013-9351, https://doi.org /10.1016/j.envres.2022.112911. Renk, H., Dulovic, A., Seidel, A. et al. Robust and durable serological response following pediatric SARS-CoV-2 infection. Nat Commun 13, 128 (2022). https://doi.org/10.1038/s41467-021-27595-9 Armann JP, Blankenburg J, Czyborra P, Doenhardt M, Horst T, Schneider J, Gano C, Berner R: SARS-CoV-2 immunity gap among schoolchildren and teachers in the summer of 2022. Dtsch Ärztebl Int 2022; 119. DOI: 10.3238/arztebl.m2022.0307 Ravens-Sieberer U, Kaman A, Devine J, Löffler C, Reiß F, Napp AK, Gilbert M, Naderi H, Hurrelmann K, Schlack R, Hölling H, Erhart M: The mental health and health-related behavior of children and parents during the COVID-19 pandemic: findings of the longitudinal COPSY study. Dtsch Ärztebl Int 2022; 119. DOI: 10.3238/arztebl.m2022.0173 (online first). Blankenburg J, Wekenborg MK, Reichert J, Kirsten C, Kahre E, Haag L, Schumm L, Czyborra P, Berner R, Armann JP. Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. Sci Rep. 2022 Feb 10;12(1):2246. doi: 10.1038/s41598-022-06166-y. PMID: 35145161; PMCID: PMC8831534. Malato J, Ribeiro RM, Leite PP, et al. Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants. N Engl J Med 2022;387:953-4. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, Meltzer L, Asraf K, Cohen C, Fluss R, Biber A, Nemet I, Kliker L, Joseph G, Doolman R, Mendelson E, Freedman LS, Harats D, Kreiss Y, Lustig Y. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022 Apr 7;386(14):1377-1380. doi: 10.1056/NEJMc2202542. Epub 2022 Mar 16. PMID: 35297591; PMCID: PMC9006792. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J , Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M , Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicenter, blinded, phase 2, randomized trial. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi:10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. PMID: 35550261; PMCID: PMC9084623. Külper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, Koch J, Köppe S, Treskova M, Vygen-Bonnet S, Waize M, Wichmann O, Harder T. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. PMID: 36091023; PMCID: PMC9449804. Radbruch A, Chang HD. A long-term perspective on immunity to COVID. Nature. 2021 Jul;595(7867):359-360. doi: 10.1038/d41586-021-01557-z. PMID: 34127832. Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, Liu Z, Kalaidina E, Thapa M, Alsoussi WB, Haile A, Klebert MK, Suessen T, Parra-Rodriguez L, Mudd PA , Whelan SPJ, Middleton WD, Teefey SA, Pusic I, O'Halloran JA, Presti RM, Turner JS, Ellebedy AH. Germinal center-driven maturation of B cell response to mRNA vaccination. Nature. 2022 Apr;604(7904):141-145. doi: 10.1038/s41586-022-04527-1. Epub 2022 Feb 15. PMID: 35168246; PMCID: PMC9204750. Kuse N, Zhang Y, Chikata T, Nguyen HT, Oka S, Gatanaga H, Takiguchi M. Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nat Commun. 2022 Sep 6;13(1):5251. doi:10.1038/s41467-022-32989-4. PMID: 36068240; PMCID: PMC9447987. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, Wellington E, Khawam J, Munro K, Cole M, Tranquillini C, Taylor-Kerr A, Hettiarachchi N, Calbraith D, Sajedi N, Milligan I, Themistocleous Y, Corrigan D, Cromey L, Price L, Stewart S, de Lacy E, Norman C, Linley E, Otter AD, Semper A, Hewson J, D'Arcangelo S, Chand M, Brown CS, Brooks T, Islam J , Charlett A, Hopkins S; SIREN Study Group. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16. PMID: 35172051; PMCID: PMC8908850. Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C; PARIS Study Group, Carreño JM, Simon V, Krammer F. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat Commun. 2022 Sep 1;13(1):5135. doi: 10.1038/s41467-022-32389-8. PMID: 6050304; PMCID: PMC9435409. Chan RWY, Liu S, Cheung JY, Tsun JGS, Chan KC, Chan KYY, Fung GPG, Li AM, Lam HS. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. Front Immunol. 2021 Oct 12;12:744887. doi:10.3389/fimmu.2021.744887. PMID: 34712232; PMCID: PMC8547269.
Additional Information
- Issue: Issue 05/2022 Publication Date: 24.06.2022 All issues as PDF Subscribe to print magazine Order single issue Open Access

